{"brief_title": "Behavior Enhances Drug Reduction of Incontinence (BE-DRI)", "brief_summary": "The primary aim of this study is to test if the addition of behavioral treatment to drug therapy for the treatment of urge incontinence will increase the number of patients who can discontinue drug therapy and sustain a significant reduction of incontinence.", "condition": ["Urinary Incontinence (UI)"], "intervention_type": ["Drug", "Behavioral"], "intervention_name": ["Tolterodine", "Behavioral training"], "description": ["4mg/d for 10 weeks. Could be reduced to 2mg/d for managing side effects.", "Training in pelvic floor muscle control and exercises; behavioral strategies to diminish urgency, suppress bladder contractions and prevent incontinence; delayed voiding; and individualized fluid management."], "arm_group_label": ["Combination therapy", "Drug therapy alone", "Combination therapy"], "criteria": "Inclusion: - Female - Urge predominant incontinence - Incontinent > 3 mos - Available for 8 mos of followup Exclusion: - Pregnancy or < 6 mos post-partum - Hypersensitivity to drug (tolterodine) - Systemic disease that affects bladder function (e.g., Parkinson's disease, Multiple Sclerosis, spinal cord injury) - History of extensive behavior treatment", "gender": "Female", "minimum_age": "21 Years", "maximum_age": "N/A", "healthy_volunteers": "Accepts Healthy Volunteers", "keyword": "Drug/Behavior treatment", "mesh_term": ["Urinary Incontinence", "Enuresis", "Tolterodine Tartrate"], "id": "NCT00090584"}